NR 565 Week 1 Discussion Condition and Rationale for Selection

Condition and Rationale for Selection

Hypothyroidism is a chronic condition in which the thyroid gland does not produce enough thyroid hormones T4 and T3, which are used in metabolism, temperature regulation, and brain development (Mayo Clinic, 2022). These are some of the symptoms likely to be experienced by patients: fatigue, dry skin, weight gain, depression, bradycardia, constipation, and cold intolerance. It may also lead to myxedema, which is a dangerous state at the advanced stage in some extreme cases. I chose hypothyroidism as it is a common endocrine disorder that could potentially cause the above symptoms to be misdiagnosed as old age in the elderly patients that I deal with in my practice. Further, the treatment of thyroid disorders requires a good understanding of pharmacokinetics and special considerations throughout the lifecycle, particularly in pregnancy, as thyroid hormones are necessary for fetal brain development.

Prescribing Recommendations and Impact on Special Populations

According to the ATA and Endocrine Society guidelines, levothyroxine (T4) is considered to be the first-line protocol of treatment for hypothyroidism. Levothyroxine has a half-life of approximately 7 days and is therefore taken once a day, early in the morning on an empty stomach, with 30-60 min before breakfast or 3-4 hours after the last meal of the day (Eghtedari & Correa, 2023). The prescription for the use of some drugs is different with the different groups of the population. In infants and children, dosing is based on weight, and neonates are typically prescribed the highest doses of the drug, as there are high thyroid hormone requirements during brain and bone development. Newborns should begin at a dose of 10-15 mcg/kg/day, and TSH and free T4 levels should be monitored monthly or every 2 months during the first year of life because of the risk for neurodevelopmental damage due to either hypo- or hyperthyroidism or overtreatment. In pregnant patients, physical changes, i.e., increased TBG levels, lead to a decrease in free thyroid hormone levels and, therefore, a 30-50% increase in levothyroxine dose is required, especially during the first trimester (Singh & Sandhu, 2021).

TSH should be tested at least 4 weeks apart until mid-pregnancy, after which it should be tested at least once in each trimester to establish a reference range for that trimester. In the elderly, it is important to consider changes in metabolism associated with aging, which increase the thyroid gland’s sensitivity to thyroid hormone, as well as the high risk of cardiovascular disease. The initiation dose is also lower in patients over 60 years of age or with ischemic heart disease; start at 12.5-25 mcg/day and increase every 6-8 weeks. Pharmacokinetic changes in the elderly population, such as decreased renal clearance and a change in protein binding, can lead to an increase in the half-life of the drug and the risk of adverse effects, such as atrial fibrillation or osteoporosis, if given in overdose – knowledge of these principles of pharmacokinetics is essential to safely, efficaciously, and personally dose in different stages of life.

Application to Future Practice

When I become a nurse practitioner, it will be very important for me to understand the pharmacokinetics and pharmacodynamics of levothyroxine to provide the most appropriate recommendations. I will use CPGs to administer and manage dosage and monitor plans that are safe and efficient. Patient education on the importance of taking the medication at the correct times, avoiding taking certain other medications (antacids, iron, calcium), and being consistent with the brand or the formulation of the medication (Salisbury & Terrell, 2023). This means that follow-ups and lab tests will be important to check on the therapeutic response to the administered therapy and prevent patients from being undertreated or overtreated. I will also champion a patient-centered approach and identify situations where the standard of care must be modified.

Strengths and Weaknesses of the CPG and Its Impact on Practice

The following paper aims to identify the CPG’s strengths and weaknesses and its impact on practice. The biggest strength of the ATA CPG is that its recommendations are graded by level of evidence and span a wide range of populations (Bautista-Orduno et al., 2020). It has recommendations with a grade A based on several randomized controlled trials and meta-analyses. The lifespan focus of the guideline aligns with the evidence for safe and patient-specific treatments for neonates, Adults, and Elderly patients. However, the guideline provides poor guidance for subclinical hypothyroidism, which is an issue that is often discussed in practice about older patients or patients with abnormal laboratory results and nonspecific symptoms.

Furthermore, although pregnancy is included in the guidelines, postpartum care is not well-defined and tends to rely more on the clinician’s judgement. In practice, I will have the graded evidence to guide my prescription and will know which recommendations have the strongest supporting evidence. However, I will also understand that patient-centered care may mean not following protocol all the time, for example, when polypharmacy, GI malabsorption, or other autoimmune disorders are present, such as hypothyroidism due to Hashimoto’s thyroiditis.

Conclusion

In conclusion, it is important to understand the pharmacological characteristics of Levothyroxine and other aspects associated with Hypothyroidism in people of different ages. The ATA clinical guidelines are based on strong evidence; however, a clinician needs to think outside the box and use their clinical judgment when diagnosing or treating patients with such disorders. These principles are important, and as a future nurse practitioner, I will apply them in my practice to provide the best possible care to patients with hypothyroidism.

TO know complete guidance about this class visit:  NR565